Biomarker analysis in recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC) patients (pts) treated with second-line afatinib versus methotrexate (MTX): LUX-Head & Neck 1 (LUX-H&N1).
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Ezra E. W. Cohen, Lisa F. Licitra, Jérôme Fayette, Thomas Christoph Gauler, Paul M. Clement, Juan José Grau, Jose Maria Del Campo, Audrey Mailliez, Robert I. Haddad, Jan B. Vermorken, Makoto Tahara, Joel Guigay, Lionnel Geoffrois, Marco C. Merlano, Nicholas F. Dupuis, Barbara Burtness, Neil Gibson, Flavio Solca, Eva Ehrnrooth, Jean-Pascal H. Machiels
Institutions: Moores Cancer Center, Fondazione IRCCS Istituto Nazionale dei Tumori, Hospices Civils de Lyon, Essen University Hospital, KU Leuven, Hospital Clínic de Barcelona, Universitat de Barcelona, Vall d'Hebron Hospital Universitari, Centre Oscar Lambret, Brigham and Women's Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Antwerp University Hospital, National Cancer Center Hospital East, Institut Gustave Roussy, Centre Antoine Lacassagne, Institut de Cancérologie de Lorraine, Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo, Fox Chase Cancer Center, Boehringer Ingelheim (Germany), Boehringer Ingelheim (Austria), Boehringer Ingelheim (Denmark), Cliniques Universitaires Saint-Luc, UCLouvain
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2767369675